Broader global access to lifesaving antiretroviral therapies and wider implementation of proven HIV prevention strategies could potentially control and perhaps end the HIV/AIDS pandemic. However, a safe and at least moderately effective HIV vaccine is needed to reach this goal more expeditiously and in a more sustainable way, according to a new commentary from Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleague Hilary D. Marston, M.D., M.P.H.
In the piece, the authors note that behavioral, cultural and legal factors have hindered HIV prevention and treatment efforts and explain why those factors necessitate the development of an HIV vaccine. Although attempts to develop a vaccine have so far proven disappointing, recent advances offer encouraging areas for HIV vaccine researchers to pursue, according to the authors. Notably, the discovery of naturally occurring broadly neutralizing antibodies against HIV and studies of their stimulation in infected individuals have opened new avenues in vaccine development. Using improved understanding of those antibodies and the specific sites on HIV to which they bind, the natural process of antibody evolution could be replicated and greatly expedited allowing protection against initial infection. Significant advances also have been made in understanding T-cell responses that may be important to vaccine-induced immunity against HIV.
The authors conclude that "the HIV prevention community should hold fast to its commitment to vaccine science. Ultimately, we believe, the only guarantee of a sustained end of the AIDS pandemic lies in a combination of nonvaccine prevention methods and the development and deployment of a safe and sufficiently effective HIV vaccine."
AS Fauci and HD Marston. Ending AIDS—Is an HIV vaccine necessary? New England Journal of Medicine DOI:10.1056/NEJMp1313771 (2014).
See NIAID Director Anthony S. Fauci, M.D., explain why an HIV vaccine is needed.
NIAID Director Anthony S. Fauci, M.D. is available for interviews.
To schedule interviews, please contact the NIAID Office of Communications, (301) 402-1663, email@example.com.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
NIH...Turning Discovery Into Health®
NIAID Office of Communications | EurekAlert!
Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Health and Medicine
06.12.2016 | Life Sciences
05.12.2016 | Power and Electrical Engineering